Affordable Access

Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.

Authors
  • Fu, Alex Z1
  • Tsai, Huei-Ting2
  • Haque, Reina3
  • Ulcickas Yood, Marianne4
  • Van Den Eeden, Stephen K5
  • Cassidy-Bushrow, Andrea E6
  • Zhou, Yingjun2
  • Keating, Nancy L7
  • Smith, Matthew R8
  • Aaronson, David S5
  • Potosky, Arnold L2
  • 1 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA. [email protected]
  • 2 Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3300 Whitehaven Street, NW, Suite 4100, Washington, DC, 20007, USA.
  • 3 Kaiser Permanente Southern California, Pasadena, CA, USA.
  • 4 Boston University School of Public Health, Boston, MA, USA.
  • 5 Kaiser Permanente Northern California, Oakland, CA, USA.
  • 6 Henry Ford Hospital, Detroit, MI, USA.
  • 7 Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • 8 Massachusetts General Hospital, Boston, MA, USA.
Type
Published Article
Journal
World journal of urology
Publication Date
December 2016
Volume
34
Issue
12
Pages
1611–1619
Identifiers
PMID: 27084777
Source
Medline
Keywords
License
Unknown

Abstract

In men with localized prostate cancer in community practice initially treated with prostatectomy or radiotherapy, sADT after primary treatment was more frequent for men at greater risk of death from prostate cancer, consistent with practice guidelines.

Report this publication

Statistics

Seen <100 times